AstraZeneca’s immunotherapy drug Imfinzi hit a second important goal by improving overall survival in lung cancer patients.
Genentech Inc. is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.
Amgen Inc. and Allergan plc. announced that the European Commission granted marketing authorization for Mvasi (biosimilar bevacizumab).
The U.S. FDA approved a supplemental NDA for Gilotrif (afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have non-resistant epidermal growth factor receptor mutations as detected by an FDA-approved test.
A cocktail of Merck & Co. Inc.’s blockbuster drug Keytruda and two chemo medicines helped lung cancer patients live longer and stopped the disease from advancing.
Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.
AstraZeneca announced that the U.S. Food and Drug Administration accepted a supplemental New Drug Application for the use of Tagrisso (osimertinib) – a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with clinical activity against central nervous system metastases – in the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have EGFR mutations.
Bristol-Myers Squibb announced that the company’s Phase III trial pitting Opdivo against chemotherapy drug docetaxel in treating certain lung cancer patients was stopped early after meeting key endpoints.
Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer.